We are live on
!
Find out more
Dianthus Therapeutics
DNTH
DNTH
51 hedge funds and large institutions have $23.6M invested in Dianthus Therapeutics in 2023 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
113% more capital invested
Capital invested by funds: $11.1M → $23.6M (+$12.5M)
33% more call options, than puts
Call options by funds: $12K | Put options by funds: $9K
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
0.16% more ownership
Funds ownership: 2.9% → 3.06% (+0.16%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
4% less funds holding
Funds holding: 53 → 51 (-2)
Holders
51
Holders Change
-2
Holders Change %
-3.77%
% of All Funds
0.81%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
13
Increased
11
Reduced
10
Closed
14
Calls
$12K
Puts
$9K
Net Calls
+$3K
Net Calls Change
-$5K
Top Buyers
Top Sellers
| 1 |
TGI
TRV GP IV
Boston,
Massachusetts
|
-$2.67M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$1.19M |
| 3 |
Millennium Management
New York
|
-$914K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$343K |
| 5 |
IHAM
Integral Health Asset Management
New York
|
-$164K |
